Sign in
BIVI Stock Price, Chart, Stats & News
BioVie Inc.
Save
13.27M
Market cap
–
Current P/E
–
Forward P/E
BIVI chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -77.48% |
ROE | -82.03% |
D/E | 0.02x |
Interest coverage ratio | -1013.71x |
BIVI valuation
P/E | – |
P/S | – |
P/B | 0.56x |
P/CF | -0.75x |
P/FCF | -0.72x |
P/OCF | -0.75x |
PEG | -0.01x |
EV multiple | -1.75x |
About
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease.
Similar securities
Based on sector and market capitalization
Report issue